company background image
6990 logo

Sichuan Kelun-Biotech Biopharmaceutical SEHK:6990 Stock Report

Last Price

HK$213.40

Market Cap

HK$42.9b

7D

16.9%

1Y

100.4%

Updated

21 Feb, 2025

Data

Company Financials +

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SEHK:6990 Stock Report

Market Cap: HK$42.9b

6990 Stock Overview

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. More details

6990 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 31.4% below our estimate of its fair value

Earnings are forecast to grow 5.08% per year

Revenue grew by 24.7% over the past year

Risk Analysis

No risks detected for 6990 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitors

Akeso

SEHK:9926

HK$61.9b

Innovent Biologics

SEHK:1801

HK$68.3b

Shanghai Junshi Biosciences

SEHK:1877

HK$26.5b

3SBio

SEHK:1530

HK$16.3b

Price History & Performance

Summary of share price highs, lows and changes for Sichuan Kelun-Biotech Biopharmaceutical
Historical stock prices
Current Share PriceHK$213.40
52 Week HighHK$223.80
52 Week LowHK$99.55
Beta0
1 Month Change33.63%
3 Month Change27.02%
1 Year Change100.38%
3 Year Changen/a
5 Year Changen/a
Change since IPO241.44%

Recent News & Updates

Recent updates

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Jun 14
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Mar 27
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Shareholder Returns

6990HK BiotechsHK Market
7D16.9%11.7%3.2%
1Y100.4%18.9%23.6%

Return vs Industry: 6990 exceeded the Hong Kong Biotechs industry which returned 18.9% over the past year.

Return vs Market: 6990 exceeded the Hong Kong Market which returned 23.6% over the past year.

Price Volatility

Is 6990's price volatile compared to industry and market?
6990 volatility
6990 Average Weekly Movement6.5%
Biotechs Industry Average Movement8.0%
Market Average Movement6.5%
10% most volatile stocks in HK Market13.9%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 6990 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6990's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20161,542Junyou Gekelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fundamentals Summary

How do Sichuan Kelun-Biotech Biopharmaceutical's earnings and revenue compare to its market cap?
6990 fundamental statistics
Market capHK$42.91b
Earnings (TTM)-HK$200.11m
Revenue (TTM)HK$2.01b

24.1x

P/S Ratio

-242.4x

P/E Ratio

Is 6990 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6990 income statement (TTM)
RevenueCN¥1.88b
Cost of RevenueCN¥713.66m
Gross ProfitCN¥1.16b
Other ExpensesCN¥1.35b
Earnings-CN¥186.61m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.82
Gross Margin61.98%
Net Profit Margin-9.94%
Debt/Equity Ratio0%

How did 6990 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 16:10
End of Day Share Price 2025/02/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is covered by 25 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Jingjing ZhangChina Merchants Securities Co. Ltd.